.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin led to strengthened progression-free as well as overall survival, resulting in FDA commendation and a brand new procedure choice for clients.